{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-004759","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.655340+00:00","generated_at":"2026-05-18T17:48:28.005389+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phio Pharmaceuticals gets SMC nod to advance PH-762 skin cancer trial to fifth cohort","bullets":["Safety Monitoring Committee recommends dose escalation to fifth (final) cohort in Phase 1b trial of INTASYL PH-762.","No dose-limiting toxicities, serious adverse events, or clinically relevant treatment-emergent reactions in fourth cohort (5 patients).","To date, 15 patients treated; pathological complete response (100% clearance) seen in 4 of 9 cSCC patients from prior cohorts.","Enrollment in final cohort expected to complete in Q3 2025.","PH-762 is an intratumoral siRNA targeting cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-004759","json":"https://secwatch.observer/filing/0001683168-25-004759.json","markdown":"https://secwatch.observer/filing/0001683168-25-004759.md","text":"https://secwatch.observer/filing/0001683168-25-004759.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825004759/0001683168-25-004759-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825004759/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:48:28.005389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}